Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Wright Reports
Provider: GlobalData

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

US FDA Grants Orphan-Drug Designation To ProMetic Life Sciences Inc's Plasma-Derived Plasminogen Drug

Thursday, 14 Mar 2013 06:30am EDT 

ProMetic Life Sciences Inc announced that an orphan drug designation status has been granted for plasma purified human plasminogen drug to ProMetic BioTherapeutics, Inc., US based subsidiary, by the American Food and Drug Administration (FDA). The orphan drug designation is for the treatment of hypoplasminogenemia, or type I plasminogen deficiency (T1PD). T1PD is a rare autosomal recessive disorder that leads to severe clinical manifestations, primarily associated with fibrous depositions on mucous membranes throughout the body. It is a multisystem disease that affects the eyes, ears, sinuses, tracheobronchial tree, genitourinary tract and gums. There is no effective replacement therapy currently available for this disease. 

Company Quote

0.01 +0.94%
11 Jul 2014